C1529556||transcription factor activating enhancer-binding protein 2C
C0024109||lung
C0596263||tumorigenesis
C1101610||miR-183
C1101610||miR-33a
C1155872||cell cycle regulation
C0007131||Non-small cell lung cancer
C0007131||Non-small cell lung cancer
C0011065||death
C2700280||worldwide
C1513403||molecular targets
C0034802||epidermal growth factor receptor
C1414313||epidermal growth factor receptor
C1537502||KRAS
C0596611||mutation
C0024109||lung
C0596263||tumorigenesis
C0034802||epidermal growth factor receptor
C0763464||KRAS
C1529556||Enhanced TFAP2C
C1529556||transcription factor activating enhancer-binding protein 2C
C1171362||expression
C3854082||prognosis
C0699748||pathogenesis
C0684249||lung cancer
C2603343||study
C1529556||transcription factor activating enhancer-binding protein 2C
C1514559||overexpression
C0007613||cell cycle activation
C0007131||Non-small cell lung cancer
C0007634||cell
C0596263||tumorigenesis
C1529556||transcription factor activating enhancer-binding protein 2C
C1454561||AKAP12
C0174680||cyclin D1
C0017262||overexpression
C2825314||oncogenic microRNA
C1537817||(miRNA)-183
C0252132||cyclin-dependent kinase 6
C1516334||cell cycle progression
C0013081||downregulating
C1101610||miRNA-33a
C2986594||mouse xenograft model
C3712863||transcription factor activating enhancer-binding protein 2C
C0024109||lung
C0596263||tumorigenesis
C1101610||miR-183
C1101610||miR-33a
C0037080||pathways
C2603343||study
C3537152||mitogenic
C3537152||oncogenic signaling
C1529556||transcription factor activating enhancer-binding protein 2C
C0007613||cell cycle hyperactivation
C0024109||lung
C0596263||tumorigenesis